Inhibikase Therapeutics, Inc.

corporate_fare Company Profile

Inhibikase Therapeutics, Inc.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed IKT - Latest Insights

Filing Type

Date Range

IKT

Apr 20, 2026, 4:05 PM EDT

Filing Type: PRE 14A

Importance Score:

8

Inhibikase Seeks Shareholder Approval for Significant Equity Plan Expansion and Officer Liability Shield

Sentiment: Negative

View Wiseek Article

IKT

Mar 26, 2026, 4:35 PM EDT

Source: Wiseek News

Importance Score:

8

Inhibikase Therapeutics Reports $48.26M Net Loss in 10-K, Operating Loss Widens to $51.97M

Sentiment: Negative

View Wiseek Article

IKT

Mar 26, 2026, 4:32 PM EDT

Filing Type: 10-K

Importance Score:

8

Annual Report Details $185M ATM Program, $48.2M Phase 3 Trial Commitment, and Significant Losses

Sentiment: Neutral

View Wiseek Article

IKT

Mar 26, 2026, 4:21 PM EDT

Filing Type: 8-K

Importance Score:

8

Inhibikase Therapeutics Initiates Global Pivotal Phase 3 Study for IKT-001 in Pulmonary Arterial Hypertension

Sentiment: Positive

View Wiseek Article

IKT

Mar 26, 2026, 4:01 PM EDT

Source: GlobeNewswire

Importance Score:

9

Inhibikase Launches Pivotal Phase 3 PAH Study for IKT-001, Reports Strong Cash Position

Sentiment: Positive

View Wiseek Article